Parag J. Parikh, MD
Parag J. Parikh, MD, Director of Gastrointestinal Radiation Oncology, Henry Ford Cancer Institute, Detroit, commented that KEYNOTE-128 “unfortunately found a very low rate of response to single-agent pembrolizumab.” He said he would not use this approach in any patients with neuroendocrine tumors because there are “other options to try.” Whether immunotherapy is worth pursuing in this tumor type will depend, added Dr. Parikh, on identifying a subset who may benefit. “We have to do something to enrich the population before taking immunotherapy further in neuroendocrine tumors.” ■
DISCLOSURE: Dr. Parikh received research funding from Viewray Inc, has intellectual property licensed to Varian Medical, and an ownership interest in Nuvaira, Inc.
Neuroendocrine tumors appear resistant to single-agent immunotherapy, according to the results of the KEYNOTE-028 trial of pembrolizumab. “Pembrolizumab monotherapy showed limited antitumor activity but a manageable safety profile in patients with previously treated, advanced neuroendocrine...